Cantor Fitzgerald upgraded Fulcrum Therapeutics (FULC) to Overweight from Neutral with a $10 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties
- Hold Rating for Fulcrum Therapeutics Amid Promising Trials and Competitive Challenges
- Fulcrum Therapeutics Reports Q1 2025 Progress and Stability
- Fulcrum Therapeutics’ Positive Earnings Call Highlights
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue